We bring you the latest news from the healthcare about the health care in the United Kingdom.

woensdag 26 september 2018

The Lancet: [News] Atezolizumab for metastatic triple-negative breast cancer

[News] Atezolizumab for metastatic triple-negative breast cancer
Results of a new study have shown that single-agent atezolizumab has durable clinical activity and was well tolerated in patients with metastatic triple-negative breast cancer.
Read more

[News] Alectinib shows CNS efficacy in ALK-positive NSCLC
Alectinib is superior to crizotinib in terms of CNS efficacy in patients with previously untreated, advanced ALK mutation-positive non-small-cell lung cancer (NSCLC), irrespective of baseline CNS metastases or previous treatment, according to a recent study.
Read more

[Articles] Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Compared with docetaxel, avelumab did not improve overall survival in patients with platinum-treated PD-L1-positive NSCLC, but had a favourable safety profile.
Read more

[Comment] Avelumab in non-small-cell lung cancer
Antibodies targeting PD-1 (eg, nivolumab and pembrolizumab), or its ligand, PD-L1 (eg, atezolizumab), are approved as second-line therapy in non-small-cell lung cancer (NSCLC). The American Society of Clinical Oncology's 2017 Clinical Practice Guideline1 recommended pembrolizumab as second-line therapy in patients with NSCLC with PD-L1 tumour proportion scores of more than 1% (ie, patients with PD-L1 expression in 1% or more tumour cells).1 In the guideline, nivolumab and atezolizumab were also recommended as second-line therapy in patients with NSCLC with any level of PD-L1 expression.
Read more

[Policy Review] National cancer control plans: a global analysis
There is increasing global recognition that national cancer plans are crucial to effectively address the cancer burden and to prioritise and coordinate programmes. We did a global analysis of available national cancer-related health plans using a standardised assessment questionnaire to assess their inclusion of elements that characterise an effective cancer plan and, thereby, improve understanding of the strengths and limitations of existing plans. The results show progress in the development of cancer plans, as well as in the inclusion of stakeholders in plan development, but little evidence of their implementation.
Read more